{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T21:14:43Z","timestamp":1716671683662},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>A protocol was started within a large health system to automatically test all confirmed extended-spectrum beta-lactamase (ESBL)\u2013producing Escherichia coli urine isolates for susceptibility to fosfomycin, an antibiotic not routinely included in such testing in most institutions. This study assessed the effectiveness of the protocol at reducing carbapenem use for the definitive treatment of ESBL E. coli urinary tract infection (UTI) through several endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eighty and 99 patients were compared pre- and postintervention, respectively. The primary outcome was the proportion of patients who received definitive carbapenem therapy. Key secondary outcomes included median total carbapenem days of therapy (DOT), discharge on intravenous UTI antibiotics, and median total antibiotic DOT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Preprotocol vs postprotocol definitive carbapenem use was seen in 59 of 80 patients (73.8%) and 71 of 99 patients (71.7%) (95% confidence interval [CI] for difference, -11.1% to 15.1%; P = 0.76). The rates of step-down to oral agents pre- and postintervention were 15 of 59 (25.4%) and 35 of 71 (49.3%) (P = 0.004). Median carbapenem DOT in those receiving carbapenems decreased from 8 to 4 days (95% CI, -5 to -1 days; P = 0.001). Median total DOT decreased from 10 to 8 days (95% CI, -3 to -1 days; P = 0.002).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Implementation of a laboratory policy to automatically test ESBL positive E. coli for fosfomycin susceptibility did not reduce the percentage of patients receiving at least 1 dose of carbapenem treatment. It did result in a larger percentage reduction in step-down use of intravenous antibiotics for UTI prior to discharge, reduction in carbapenem DOT, and reduction in total antibiotic DOT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaa174","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T11:07:07Z","timestamp":1598353627000},"page":"S105-S110","source":"Crossref","is-referenced-by-count":4,"title":["Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum \u03b2-lactamase <i>Escherichia coli<\/i> urinary tract infection treatment"],"prefix":"10.1093","volume":"77","author":[{"given":"Kevin","family":"Deemer","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mease Countryside Hospital, Safety Harbor, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Grey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mease Countryside Hospital, Safety Harbor, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Fronczek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mease Countryside Hospital, Safety Harbor, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Marr","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mease Countryside Hospital, Safety Harbor, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"issue":"12","key":"2020120619093161900_CIT0001","doi-asserted-by":"crossref","first-page":"e0220265","DOI":"10.1371\/journal.pone.0220265","article-title":"The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017","volume":"14","author":"Critchley","year":"2019","journal-title":"PLoS One."},{"issue":"5","key":"2020120619093161900_CIT0002","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1074\/jbc.M411325200","article-title":"Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release","volume":"280","author":"Eschenburg","year":"2005","journal-title":"J Biol Chem."},{"issue":"17","key":"2020120619093161900_CIT0003","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA."},{"key":"2020120619093161900_CIT0004","first-page":"66","article-title":"Fosfomycin for urinary tract infections","volume":"39","year":"1997","journal-title":"Med Lett Drugs Ther"},{"issue":"5","key":"2020120619093161900_CIT0005","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis."},{"issue":"2","key":"2020120619093161900_CIT0006","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jac\/dkn177","article-title":"Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in the Netherlands?","volume":"62","author":"Knottnerus","year":"2008","journal-title":"J Antimicrob Chemother."},{"issue":"17","key":"2020120619093161900_CIT0007","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","article-title":"Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"168","author":"Rodr\u00edguez-Ba\u00f1o","year":"2008","journal-title":"Arch Intern Med."},{"issue":"2","key":"2020120619093161900_CIT0008","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1128\/AAC.02614-15","article-title":"Activity of fosfomycin against extended-spectrum-\u03b2-lactamase-producing uropathogens in patients in the community and hospitalized patients","volume":"60","author":"Linsenmeyer","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"2020120619093161900_CIT0009","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12879-016-1888-1","article-title":"Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study","volume":"16","author":"Matthews","year":"2016","journal-title":"BMC Infect Dis."},{"issue":"1","key":"2020120619093161900_CIT0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/jgid.jgid_72_17","article-title":"Nitrofurantoin and fosfomycin for extended spectrum beta-lactamases producing Escherichia coli and Klebsiella pneumoniae","volume":"10","author":"Tulara","year":"2018","journal-title":"J Glob Infect Dis."},{"issue":"1","key":"2020120619093161900_CIT0011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections","volume":"29","author":"Pullukcu","year":"2007","journal-title":"Int J Antimicrob Agents."},{"issue":"1","key":"2020120619093161900_CIT0012","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","article-title":"Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections","volume":"48","author":"Veve","year":"2016","journal-title":"Int J Antimicrob Agents."},{"issue":"6","key":"2020120619093161900_CIT0013","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jac\/dkr137","article-title":"Impact of antimicrobial stewardship in critical care: a systematic review","volume":"66","author":"Kaki","year":"2011","journal-title":"J Antimicrob Chemother."},{"issue":"9","key":"2020120619093161900_CIT0014","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.medmal.2006.07.012","article-title":"[Impact of antibiotic use and prescribing policy in a Tunisian intensive care unit]","volume":"36","author":"Brahmi","year":"2006","journal-title":"Med Mal Infect."},{"issue":"1","key":"2020120619093161900_CIT0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00134-002-1565-2","article-title":"Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs","volume":"29","author":"Geissler","year":"2003","journal-title":"Intensive Care Med."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/Supplement_4\/S105\/34322163\/zxaa174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/Supplement_4\/S105\/34322163\/zxaa174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T01:06:56Z","timestamp":1607303216000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/Supplement_4\/S105\/5896883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":15,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2020,8,25]]},"published-print":{"date-parts":[[2020,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa174","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,8,25]]}}}